Chronic idiopathic thrombocytopenic purpura: Mechanisms of pathogenesis

Oncologist

Volumn 14, Issue 1, 2009, Pages 12-21

  Gernsheimer, Terry ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

ITP; Platelets; Thrombocytopenia; Thrombopoietin

Indexed keywords

AKR 501; AZATHIOPRINE; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANAZOL; ELTROMBOPAG; IMMUNOGLOBULIN; LGD 4665; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RECOMBINANT THROMBOPOIETIN; RHESUS D ANTIBODY; RITUXIMAB; ROMIPLOSTIM; THROMBOCYTE ANTIBODY; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; TYROSINE; UNCLASSIFIED DRUG; VINCA ALKALOID;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CATARACT; CELLULAR IMMUNITY; CYTOTOXIC LYMPHOCYTE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MEGAKARYOPOIESIS; NATURAL KILLER CELL; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SPLENECTOMY; T LYMPHOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOEMBOLISM; TREATMENT RESPONSE;

BLOOD PLATELETS; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 61449111086     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0132     Document Type: Article

References (81)

1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
2. Coopamah MD, Garvey MB, Freedman J et al. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus Med Rev 2003;17:69-80.
3. Kuwana M, Ikeda Y. The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol 2005;81:106 -112.
4. 111Inlabeled platelets and homologous 51Cr-labeled platelets differ. Blood 1986; 67:86 -92.
5. Branehög I, Kutti J, Weinfeld A. Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 1974; 27:127-143.
6. Gernsheimer T, Stratton J, Ballem PJ et al. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. N Engl J Med 1989; 320:974 -980.
7. Harrington WJ, Minnich V, Hollingsworth JW et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951;38:1-10.
8. Harrington WJ, Sprague CC, Minnich V et al. Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 1953; 38:433- 469.
9. Shimomura T, Fujimura K, Takafuta T et al. Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura. Br J Haematol 1996;95:732-737.
10. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000;37:239 -248.
11. Escher R, Muller D, Vogel M et al. Recombinant human natural autoantibodies against GPIIb/IIIa inhibit binding of autoantibodies from patients with AITP. Br J Haematol 1998;102:820-828.
12. Kunicki TJ, Newman PJ. The molecular immunology of human platelet proteins. Blood 1992;80:1386 -1404.
13. He R, Reid DM, Jones CE et al. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994;83:1024 -1032.
14. Stratton JR, Ballem PJ, Gernsheimer T et al. Platelet destruction in autoimmune thrombocytopenic purpura: Kinetics and clearance of indium-111-labeled autologous platelets. J Nucl Med 1989;30:629-637.
15. Kravitz MS, Shoenfeld Y. Thrombocytopenic conditions-autoimmunity and hypercoagulability: Commonalities and differences in ITP, TTP, HIT, and APS. Am J Hematol 2005;80:232-242.
16. Roark JH, Bussel JB, Cines DB et al. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 2002;100:1388 -1398.
17. Kiefel V, Freitag E, Kroll H et al. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia. Ann Hematol 1996;72:280 -285.
18. McMillan R, Tani P, Millard F et al. Platelet-associated and plasma antiglycoprotein autoantibodies in chronic ITP. Blood 1987;70:1040 -1045.
19. van Leeuwen EF, van der Ven JT, Engelfriet CP et al. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982;59:23-26.
20. Kelton JG, Powers PJ, Carter CJ. A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. Blood 1982;60:1050 -1053.
21. Fabris F, Scandellari R, Ruzzon E et al. Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 2004;103:4562- 4564.
22. Semple JW, Milev Y, Cosgrave D et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: Relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996;87: 4245-4254.
23. Wang T, Zhao H, RenHet al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 2005;90:914 -923.
24. Olsson B, Andersson P-O, Jernas M et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003;9:1123-1124.
25. Andersson PO, Stockelberg D, Jacobsson S et al. A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann Hematol 2000;79:507-513.
26. Zhang F, Chu X, Wang L et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006;76: 427-431.
27. Gernsheimer T. Pathophysiology and thrombokinetics in autoimmune thrombocytopenia. Blood Rev 2002;16:7- 8.
28. Li S, Wang L, Zhao C et al. CD8+T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura. Br J Haematol 2007;139:605- 611.
29. Garcia-Suarez J, Prieto A, Reyes E et al. Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+ CD3- natural killer cells subset. Blood 1993;82:1538 -1545.
30. Kuter DJ. The physiology of platelet production. STEM CELLS 1996; 14(suppl 1):88 -101.
31. Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969;48: 963-974.
32. Ballem PJ, Segal GM, Stratton JR et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987;80:33- 40.
33. Stoll D, Cines DB, Aster RH et al. Platelet kinetics in patients with idiopathic thrombocytopenic purpura and moderate thrombocytopenia. Blood 1985;65:584 -588.
34. Kiefel V, Becker T, Mueller-Eckhardt G et al. Platelet survival determined with 51Cr versus 111In. Klin Wochenschr 1985;63:84-89.
35. McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol 2005;81:94 -99.
36. McMillan R, Luiken GA, Levy R et al. Antibody against megakaryocytes in idiopathic thrombocytopenic purpura. JAMA 1978;239:2460 -2462.
37. Houwerzijl EJ, Blom NR, van der Want JL et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004; 103:500 -506.
38. Chang M, Nakagawa PA, Williams SA et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003;102:887- 895.
39. Mukai HY, Kojima H, Todokoro K et al. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost 1996;76:675- 678.
40. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115:3339 -3347.
41. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: A pan-hematopoietic cytokine. Cytokine Growth Factor Rev 2002;13:61-73.
42. Hunt P, Li YS, Nichol JL et al. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 1995;86:540 -547.
43. Bartley TD, Bogenberger J, Hunt P et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994;77:1117-1124.
44. Chen J, Herceg-Harjacek L, Groopman JE et al. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995;86: 4054-4062.
45. Oda A, Miyakawa Y, Druker BJ et al. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996;87:4664-4670.
46. Van Os E, Wu YP, Pouwels JG et al. Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br J Haematol 2003;121: 482- 490.
47. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995;85:2720 -2730.
48. Li J, Xia Y, Kuter D. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: Binding, internalization, stability and pharmacokinetics. Br J Haematol 1999;106:345-356.
49. Cerutti A, Custodi P, Duranti M et al. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997;99:281-284.
50. Kosugi S, Kurata Y, Tomiyama Y et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996;93:704-706.
51. Emmons RVB, Reid DM, Cohen RL et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996;87:4068 -4071.
52. Aledort LM, Hayward CPM, Chen M-G et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004;76:205-213.
53. Ichikawa N, Ishida F, Shimodaira S et al. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb Haemost 1996;76: 156-160.
54. Tarantino MD, Stephens DM, Imfeld KL et al. The effect of tumor necrosis factor (TNFα) inhibition on platelet counts in adults and children with persistent ITP. Blood 2006;108:1075.
55. Schwartz J, Bussel JB. Anti-CD40L: Biology and therapy in ITP. Blood 2004;103:1178 -1179.
56. Zhang WG, Ji L, Cao XM et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenia purpura. Acta Pharmacol Sin 2005; 26:598-602.
57. Chang M, Suen Y, Meng G et al. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: Insight into the regulation of platelet production. Blood 1996; 88:3354 -3362.
58. Kuter DJ, Bussel JB, Aledort LM et al. A phase 2 placebo controlled study evaluating the platelet response and safety of weekly dosing with a novel t thrombopoietic protein (AMG531) in thrombocytopenic patients with immune thrombocytopenic purpura (ITP). Blood 2004;104:511.
59. Erickson-Miller CL, DeLorme E, Tian SS, Hopson CB et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005;33:85-93.
60. Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357: 2237-2247.
61. Basser RL, Underhill C, Davis I et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 2000;18:2852-2861.
62. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000;132:364 -368.
63. Basser RL, O'Flaherty E, Green M et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002;99:2599 -2602.
64. Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008;371:395- 403.
65. Desjardins R, Tempel D, Lucek R et al. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood 2006;108:477.
66. Bussel JB, Kuter DJ, George JN et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-1681.
67. Kuter D, Bussel J, Senecal F et al. Evaluation of AMG 531 efficacy in nonsplenectomized patients with chronic immune thrombocytopenic purpura (ITP) in a randomized placebo-controlled phase 3 study. Blood 2007;110:565.
68. Gernsheimer T, Pullarkat V, Senecal F et al. Evaluation of AMG 531 efficacy in splenectomized patients with chronic immune thrombocytopenic purpura (ITP) in a randomized placebo-controlled phase 3 study. Blood 2007;110:2.
69. Bussel JB, Kuter DJ, de Wolf DJ et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 2-year update. Blood 2007;110:568.
70. Lyons R, George J, Lefrere F et al. Evaluation of AMG 531 safety in splenectomized (S) and nonsplenectomized (NS) patients with chronic immune thrombocytopenic purpura (ITP) in two randomized placebo-controlled phase 3 studies. Blood 2007;110:1300.
71. Luengo J, Duffy K, Shaw A et al. Discovery of SB-497115, a smallmolecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood 2004;104:2910.
72. Bussel J, Provan A, Shamsi T et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: A phase III study. Haematologica 2007;92(suppl 1):143.
73. Bussel J, Cheng G, Kovaleva L et al. Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): Preliminary data from the EXTEND study. Blood 2007;110:566.
74. Jenkins JM, Williams D, Deng Y et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739-4741.
75. U.S. Food and Drug Administration. Promacta (Eltrombopag Tablets). FDA Oncologic Drug Advisory Committee Briefing Document. Available at http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4366bl-02-GSK.pdf, accessed October 22, 2008.
76. Bussel J, McHutchison J, Provan D et al. Safety of eltrombopag, an oral non-peptide platelet growth factor, in the treatment of thrombocytopenia: Results of four randomized, placebo-controlled studies. Blood 2007;110:1299.
77. Nplate [package insert]. Thousand Oaks, CA: Amgen Inc, 2008.
78. U.S. Food and Drug Administration. Background Information for the Oncologic Drug Advisory Committee (ODAC) Meeting 12 March 2008. Available at http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345bl-02-AMGEN.pdf, accessed October 23, 2008.
79. Bennett D, Forssen U, Enger C et al. Risk of thromboembolic events among patients with chronic idiopathic thrombocytopenic purpura (ITP). Haematologica2008;93(suppl 1):125.
80. Evangelista ML, Amadori S, Stasi R. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. Curr Drug Discov Technol 2007;4:162-173.
81. Dziewanowska ZE, Matsumoto RM, Zhang JK et al. Single and multiple oral doses of LGD-4665, a small molecule thrombopoietin receptor agonist, increase platelet counts in healthy male subjects. Blood 2007; 110:1298.